Sanofi Weighs Takeover Bid for Insmed, Bloomberg Reports
INSM sits 42% above its 52-week low of $90.39 on light trading volume (0.2× avg).
Summary
Bloomberg reports Sanofi is weighing a takeover of Insmed, a US biotech with a fast-growing bronchiectasis franchise. Insmed's Q3 revenue hit $524.4 million, up 268% year over year, on $398.1 million of US BRINSUPRI sales, and the company raised full-year guidance — a commercial profile that makes it a credible strategic target for a large pharma buyer. The report is early-stage: no price, no confirmed talks, and no Sanofi confirmation, so the terms and certainty are unknown. Insmed's board also added Paul Hudson, Sanofi's former CEO, in October, which gives the two companies an existing high-level link.
At the time of this announcement, INSM was trading at $128.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.1B. The 52-week trading range was $90.39 to $212.75. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.